{"id":520997,"date":"2021-08-02T06:03:21","date_gmt":"2021-08-02T10:03:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"modified":"2021-08-02T06:03:21","modified_gmt":"2021-08-02T10:03:21","slug":"biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","title":{"rendered":"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference"},"content":{"rendered":"

<\/p>\n

Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference<\/b><\/p>\n

BOULDER, Colo.–(BUSINESS WIRE<\/a>)–Biodesix, Inc.<\/a> (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021.\n<\/p>\n

Canaccord Genuity 41st Annual Growth Conference<\/b><\/p>\n

\nDate: Thursday, August 12, 2021
\n
Time: 12:30 PM ET\n<\/p>\n

\nThe presentation will be webcast live and available for replay under \u201cNews & Events\u201d in the Investors section of the Company’s website at www.biodesix.com<\/a>.\n<\/p>\n

About Biodesix<\/b><\/p>\n

\nBiodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR\u2122 test, the Platelia SARS-CoV-2 Total Ab, and the cPass \u2122 SARS-CoV-2 Neutralization Antibody test (cPass\u2122 Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex\u00ae strategy for lung cancer patients integrates the GeneStrat\u00ae and VeriStrat\u00ae tests to support treatment decisions with results in 36 hours, expediting time to treatment. The blood-based Nodify Lung\u00ae nodule risk assessment testing strategy, consisting of the Nodify XL2\u00ae and the Nodify CDT\u2122 tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also leverages the proprietary and advanced Diagnostic Cortex\u00ae AI platform, to collaborate with many of the world\u2019s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.\n<\/p>\n

Note Regarding Forward-Looking Statements<\/strong><\/p>\n

\nThis press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201copportunity,\u201d \u201cgoals,\u201d or \u201cshould,\u201d and similar expressions are intended to identify forward-looking statements. Such statements are based on management\u2019s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix\u2019s most recent annual report on Form 10K, filed March 16, 2021. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210802005124\/en\/<\/a><\/span><\/p>\n

Media:
\n<\/b>
Bobbi Coffin
\n
bobbi.coffin@biodesix.com
\n<\/a>
(303) 892-3203<\/p>\n

Investors:
\n<\/b>
Chris Brinzey
\n
chris.brinzey@westwicke.com
\n<\/a>
(339) 970-2843\n<\/p>\n

KEYWORDS:<\/b> United States North America Colorado<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021. Canaccord Genuity 41st Annual Growth Conference Date: Thursday, August 12, 2021 Time: 12:30 PM ET The presentation will be webcast live and available for replay under \u201cNews & Events\u201d in the Investors section of the Company’s website at www.biodesix.com. About Biodesix Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining … <\/p>\n

Continue reading “Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-520997","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBiodesix to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021. Canaccord Genuity 41st Annual Growth Conference Date: Thursday, August 12, 2021 Time: 12:30 PM ET The presentation will be webcast live and available for replay under \u201cNews & Events\u201d in the Investors section of the Company’s website at www.biodesix.com. About Biodesix Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining … Continue reading "Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-02T10:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference\",\"datePublished\":\"2021-08-02T10:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"wordCount\":628,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\",\"name\":\"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-08-02T10:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","og_description":"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021. Canaccord Genuity 41st Annual Growth Conference Date: Thursday, August 12, 2021 Time: 12:30 PM ET The presentation will be webcast live and available for replay under \u201cNews & Events\u201d in the Investors section of the Company’s website at www.biodesix.com. About Biodesix Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining … Continue reading \"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-02T10:03:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference","datePublished":"2021-08-02T10:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"wordCount":628,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","name":"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-08-02T10:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210802005124r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=520997"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520997\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=520997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=520997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=520997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}